Technology Boss

What's function in a Valley?

Last year we was a Biodesign Fellow during Stanford University. we wrote, each 6 weeks, about a ultimate apportionment of a fellowship. we posted upon my knowledge with creation from a sanatorium room by PubMed research, by white house brainstorms as well as engineering design, in to prototyping, marketplace research, as well as behind to design. Now we am posting something else; we am repositioning, if we will, to yield answers to what we many wish to listen to about, from a Valley.

The brotherhood we undertook gave me an implausible knowledge as well as a unusual network. And, what seems to apart this place from others is, in part, some-more capital, though in a vast part, some-more experience. As a window in to this world, we would adore to listen to your questions as well as afterwards yield answers, from a most appropriate as well as a brightest people here in a Valley. So, if we have been an dignitary in disinfectant or engineering, or any alternative margin where device imagination could be valuable, greatfully email divided (joelleabra@gmail.com) or post comments here as well as we will post answers to them.

A couple of which we have answered for myself not long ago are: do incubators work? What is this manage to buy seeking similar to here as well as how will which begin a future? Will a FDA each be accessible again? Does Canada have a possibility during rival creation as well as what separates it from a Valley? What have been innovative selling strategies? What is a worth of a commercial operation chairman in a early stages of a company? How can we make up a start-up for success? How should partners “try prior to they buy”? What is vicious for a startup group to know? What can we sense from pharma companies as well as corporate amicable responsibility? … a questions have been endless, so if we send yours, we will begin there.

I demeanour brazen to on condition which a discernment as well as connectors which we can from this partial of a world.

In new years, India has witnessed fast changes in a patenting landscape as a outcome of a flourishing mercantile wake up as well as reforms (related to patents).  In May 2008, Evalueserve, a tellurian investigate as well as analytics firm, investigated a patenting landscape in India , focusing upon a obvious applications published over 2005–07.

Some of a pass commentary of a patenting landscape investigate over a past 4 years (January 2005 to Dec 2008) have been listed below:

• Reduced expansion in obvious filings: The series of applications filed by unfamiliar field globally fell in 2008 since of a mercantile downturn. Since some-more than 80% of a applications filed with a Indian Patent Office (IPO) have been from unfamiliar applicants, a expansion in IPO filings gifted over a past couple of years has slowed down considerably.
• Top filers: Qualcomm has emerged as a tip obvious filer for a dual uninterrupted years—2007 as well as 2008. General Motors, General Electric, Tata Group, LG Electronics, Research in Motion, 3M as well as Sony Ericsson have done outrageous gains in their 2008 rankings. The rankings of Philips, Bayer, Microsoft as well as AstraZeneca have slipped marginally.
• Domestic pharma zone maintains a lead over alternative industries: A sum of 6 made during home pharma companies found place in a list of tip 100 filers during 2005–08. Among these 6 corporations, Ranbaxy Laboratories emerged as a tip filer (rank 31), followed by Dr. Reddy’s Laboratories (rank 45) as well as Cadila Healthcare (rank 66).
• Not most shift in a made during home report technology (IT) sector: In a made during home IT sector, a series of published obvious applications of Infosys as well as TCS increasing in 2008. Infosys had twenty-five published applications in 2008 as opposite nineteen in 2007.

Patent Application Filings during a IPO

During a past 6 years, a series of obvious applications filed with a IPO has increasing threefold. This has been essentially due to multinational companies environment up as well as expanding their markets in India.  The tip twenty-five filers list includes eleven corporations from a wiring as well as telecom domain, as well as 8 from a pharmaceuticals as well as chemicals domain.

There is an enlarge in a series of field coming a courts to make their patents or severe a effect of patents, or even severe a decisions of a IPO. Reports indicate that, in 2008, a series of patent-related cases were tentative in assorted Indian courts; some-more than 175 cases were tentative in a Delhi High Court, together with Roche vs. Cipla.

Since obvious hold up cycle spans twenty years, it is transparent which Indian corporations need to delineate their patenting plan delicately to stay competitive. This will inhere formulating some-more innovations, safeguarding all innovations with a applicable form of IP, with regard to others’ IP as well as extracting worth from own IP by licensing, commercialization as well as enforcement.

The on top of is from a article, “Patent Landscape in India Evalueserve White Paper Oct 2009,” as well as is used by permission.  The essay is authored by Balwant Rawat, a Group Manager with a Intellectual Property (IP) Division of Evalueserve.

Evalueserve provides believe services to a tellurian customer bottom of Fortune 5000 companies, together with Investment, Commercial as well as Retail Banks; Insurance Companies; Private Equity Firms; Corporates; Consulting as well as Research Firms; Law Firms as well as Intellectual Property Firms. Evalueserve’s imagination covers areas such as Financial as well as Investment Research, Business Research, Market Research, Intellectual Property, Data Analytics as well as Knowledge Technology Services.  The solitary owners of copyright is Evalueserve as well as make use of of a stable element is by accede only.

Related posts:

1. There’s Only One-Way to Test Double Patenting: Don’t Present Claims Too Late In an additional blow opposite late claiming, a Court of Appeals…
2. IP Enforcement in China. Or, How we Turned A $70 Filing Fee in to $23M in Cash Schneider Electric, a provider of energy as well as carry out solutions headquartered…
3. Double Jeopardy: Later Developments Can Overcome Double Patenting In Takeda Pharma v. John J. Doll (08-1131), a US…

Related posts brought to we by Yet Another Related Posts Plugin.

I only longed for to note which a complete BioCentury “Back to School” emanate referred to in a post below can right away be read for free (PDF). Thanks to a folks over there for you do this! The strange post has been updated as well.

Social entrepreneurs: Not we do enough?

It takes a little courage to mount up in front of 500+ amicable entrepreneurs as good as enablers as good as discuss it them which they aren’t we do sufficient to assistance a world’s poor. Especially if you’re an invited orator during a Social Enterprise World Forum, which usually wrapped up final Thursday, Oct 8 in Melbourne, Australia. However, it could good infer a most helpful recommendation as people conduct behind to their enterprises as good as go upon upon their good work.

At his annual event, a Clinton Global Initiative this September, former U.S. President Bill Clinton voiced Andy Kuper to a assembly as a subsequent Muhammad Yunus. Yunus was a owner of a Grameen Bank as good as leader of a 2006 Nobel Prize for his micro-credit system, assisting mangle a cycle of poverty. That’s a little large boots to fill as good as Kuper knows it. At a Social Enterprise World Forum, Kuper spoke to a representatives about his brand new initiative, Leapfrog – a micro-insurance association identical in suggestion to micro-credit, charity coverage to low-income people in building nations. He aims to strech twenty-five million people in Leapfrog’s initial proviso of development. This man thinks big.

During a mostly tongue-in-cheek discuss upon a second day of a Forum, Kuper came out swinging. While praising a efforts of most amicable entrepreneurs, Kuper was vicious of this commercial operation zone observant which most still had not worked out how to scale as good as lacked a prophesy as good as collateral to plunge into a greatest amicable issues – not a slightest of which was a 4 billion very hungry people in a world.

Kuper pronounced which a usually approach to assistance 4 billion people is to rivet large business. Companies similar to Google as good as General Electric have been a usually organizations with sufficient income as good as sufficient knowledge to work during scale. This was a bone of row amongst representatives as debates one after another via a Forum about a worth of tiny scale enterprises in ancillary exposed communities. we hold it doesn’t have to be either/or, though both/and in this debate. There’s copiousness of room for shift opposite scale as good as large commercial operation positively has to play.

Kuper’s indicate was good food for suspicion as good as positively convinced most in foster of a disastrous group in a discuss titled, There’s no commercial operation similar to amicable business. He is a challenging opponent. Good thing he is a amicable businessman himself.

Hear a full discuss here as good as discuss it us what we think.

Moderator:
Professor Peter Shergold AC – Centre for Social Impact, Australia

For a affirmative:
Alastair Wilson – School for Social Entrepreneurs, UK (Captain)
Kris Prendergast – Social Enterprise Alliance, USA
Jodie Sizer – Ingenuity Business Consulting, Australia

For a negative:
Rebecca Scott – STREAT, Australia
Dr. Andy Kuper – Leapfrog, USA & Middle East (Captain)
Dr. Nir Tsuk – Ashoka, Israel

Click Here for More Images
Originally uploaded by John Mack

I outlayed a final couple of days in Washington, DC as well as upon Skyline Drive in a Shenandoah National Park, VA. Here’s What it looked similar to from a front doorway of a room during a Skyland Resort upon a initial day – October 19, 2009.

The Partnership for New York City as well as a New York City Economic Development (NYCEDC) Corporation voiced which a New York City Investment Fund (NYCIF) will yield up to $1.25 million for a BioAccelerate NYC Prize in a foe which will yield appropriation for biomedical translational research.  The BioAccelerate NYC Prize is a citywide foe targeting commercialization of a biomedical investigate conducted in New York.

The idea of BioAccelerate NYC Prize is to interpret laboratory discoveries in to jobs as well as blurb operation growth in a city.   Applications will be reviewed by a row of experts from a investment, financial as well as hold up sciences industries as well as up to twelve finalists will be invited to have presentations during a week of Jan 25.

Three to 5 winners will be selected, with any awarded up to $250,000 in funding.  NYCIF will embrace a commission of income from a successful commercialization of products saved by a BioAccelerate NYC Prize to concede NYCIF to go on appropriation a single some-more commercialization efforts in hold up sciences.

The foe is open to researchers dependent with not-for-profit universities as well as investigate institutions in New York City.  To be eligible, an applicant’s investigate should be during a theatre which is roughly ready to be commercialized as a product which will urge tellurian health.  Finalists will be mentored by a single or dual hold up sciences attention entrepreneurs as well as have entrance to obvious as well as regulatory imagination in sequence to assistance labour their project’s blurb potential.  Winners will go on to work with a attention entrepreneurs towards commercialization as well as association formation.

For some-more report about a bioscience initiative, revisit nycbiotech.org.

The application for this competition will be accessible starting Thursday, Oct 15, 2009.  Entries for a BioAccelerate NYC Prize contingency be submitted by Nov 25, 2009.

The Wall Street Journal’s Health Blog got a possibility to ask a higher-ups during Pfizer what their R&D will demeanour similar to a year from now. Their (understandably) not too-in-depth answers have been here: Decentralized investigate units, with a little functions run company-wide, as well as this quote: “There have been elements of drug find as well as growth where you only need scale”.

Well played! you wouldn’t design anything less. But have been there elements of drug find as well as growth where scale – massive, ponderous, hundreds-of-vice-presidents scale – essentially hurts? you do not consider you’re starting to listen to that subject brought up unequivocally most during Pfizer, during slightest not out in a open. And let’s not pile those dual functions together: drug growth benefits from a company’s distance a lot some-more than drug find does. Once you’ve gotten to a critical-mass level, perfect distance (as distant as you can see) does zero to assistance capability in drug discovery, as well as essentially seems to repairs it. As justification for that statement, let me indicate to Pfizer’s inner investigate record, as opposite to a things they’ve left out as well as bought.

And what competence be lovely is an acknowledgment that large mergers – drag-on-for-months am-I-going-to-still-be-here mergers – come with an strident capability chastisement no have a difference what. you might have longed for it, though you do not stop conference any one from Pfizer contend anything similar to “Although you know that this is starting to be a outrageous disruption, you consider that in a finish it’ll be value it”. No, it regularly seems to be a Day One, hit-the-ground-running, now-the-synergy-starts stuff, that is only not in sync with reality.

Well, you can come behind in a year as well as see what Pfizer’s R&D operation unequivocally looks like. But I’ll try a guess: huge. Unwieldy. Not as prolific as you’d consider it should be. Still rearranging as well as removing not as large as a association tries to figure out how to have it all work. And seeking over a shoulder for a subsequent large acquisition. Anyone wish to gamble opposite any of those?

(1) Bnet Pharma upon “How Not to Write a Pharma Press Release“. Privately hold Epeius is promulgation out bulletins installed with phrases similar to “more overwhelming results” as well as “Epeius Biotechnologies draws a prolonged knife of targeted gene smoothness from a mill of chemistry as well as physics”. If they were publicly traded, this would be fun to watch. . .

(2) The climb of Micropharma? We’ll come behind to this subject:

The drug find pipelines of a vital curative companies have turn shockingly depleted, indication a intensity predicament in a capability of Big Pharma to encounter a curative final combined by a ever-changing spectrum of tellurian disease. However, from this vital predicament is rising a vital opportunity, namely micropharma – academia-originated biotech start-up companies which have been efficient, innovative, product-focused, as well as small. In this Feature, we plead a “new ecosystem” for drug development, with high-risk creation in micropharma heading to Big Pharma clinical trials. . .

(3) Cleaving amyloid predecessor protein in to beta-amyloid has prolonged been suspicion (by many) to be a pass pathological eventuality in Alzheimer’s. But what about a square of APP that’s left inside a cell?

(4) A a one preferred post around here for a little time has been “Sand Won’t Save You This Time“, about a wonderfulness of chlorine trifluoride. Well, here’s a method to furnish really interesting-looking compounds which uses. . .bromine trifluoride. How most do we wish these products, that’s what we have to ask yourself. To be sure, a authors do discuss which “Although commercial, bromine trifluoride is not a usual reagent in each organic laboratory, as well as most chemists do not feel during palliate with it since of a tall reactivity. . .”. You have to go to a Supporting Information record prior to we begin conference about creatively scheming a things from component fluorine.

Watch a video: Different Types of Entrepreneurship

At final week’s CIBC Presents Entrepreneurship 101 lecture, we talked about a assorted sorts of businesses, together with a critical differences in between amicable role ventures (based upon achieving a tangible amicable goal as great as creation money) as great as normal particularly for-profit businesses.

This begs an engaging subject – that indication in conclusion can grasp a many good?

If we demeanour during a bulk of charities around today, a names upon them still simulate increase done a era (at least) ago. The commercial operation people during a back of a businesses that done all a increase operation from required rarely focused as great as successful capitalists by to (lets be blunt) robber barons!

They share(d) a consecutive model: have as most as we presumably can first, afterwards confirm how to discharge a increase to estimable causes. Contrast that to a fast rising indication of amicable entrepreneurship in that we have income as great as do great during a same time.

Does any one out there wish to jeopardy an perspective as to that can broach a limit great over a prolonged haul?

Downloads as great as Resources

Weren’t means to attend a class? Need a little records or wish to demeanour something up? Click next for all of a something good to eat from a lecture. Watch a video as great as a slip display below.

• Class Summary: Different sorts of entrepreneurship
  
• Video: “Different sorts of entrepreneurship”
• Join a Facebook Group: CIBC Presents Entrepreneurship 101
• Register to get a weekly email updates

CIBC presents Entrepreneurship 101 2009/10 – Week 3 – Different Types of Entrepreneurship from MaRS Discovery District upon Vimeo.

I usually perceived acknowledgment from Jean-Ah Kang, Special Assistant to Tom Abrams during DDMAC in assign of Web 2.0 process development, which we will be presenting a formula of a consult “FDA’s Regulation of Drug & Device Promotion around a Internet & Social Media” during a Nov 12-13, 2009 open conference in Washington, D.C.

To date, there have been over 250 responses to this survey. My idea is to have during slightest 350 responses by November. So, if we have not already taken a consult — which seeks opinions upon a 5 topics of seductiveness to a FDA — greatfully do it right away to get your perspective counted. Of course, we can additionally contention your comments without delay to a FDA, though a consult is a usually well known instrument which allows a quantitative analysis of specific solutions which residence FDA’s concerns.

To reply to a consult right now, click here.